<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5478">
  <stage>Registered</stage>
  <submitdate>16/04/2007</submitdate>
  <approvaldate>16/04/2007</approvaldate>
  <nctid>NCT00461409</nctid>
  <trial_identification>
    <studytitle>IV Levetiracetam for the Treatment of Neonatal Seizures: a Pharmacokinetic and Preliminary Efficacy and Safety Study</studytitle>
    <scientifictitle>Phase I/II Study of IV Levetiracetam as an add-on Drug for Seizures in Term Neonates Assessing Pharmacokinetics, Safety and Efficacy.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NeoLev 1</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Seizures</healthcondition>
    <healthcondition>Term Neonates</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Epilepsy</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Intravenous levetiracetam

Experimental: Open Lable Treatment with Levetiracetam - IV loading for persistent neonatal seizure after phenobarbital with levetiracetam 20 or 40 mg/kg bolus followed by 5-10 mg/kg/d


Treatment: drugs: Intravenous levetiracetam
IV levetiracetam escalating to 40mg/kg load and daily 10mg/kg maintenance

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pharmacokinetic data on intravenous levetiracetam administered to term neonates over 7 days.</outcome>
      <timepoint>Study completion</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Preliminary safety data and efficacy data will be collected.</outcome>
      <timepoint>Study completion</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Newborns admitted with seizures to the UCSD, Children's Hospital or Sharp Mary Birch
             NICUs in San Diego, CA, USA as well as Auckland City Hospital, Grafton,Auckland NZ :

          -  Term infants (gestational age greater than or equal to 37 weeks &gt; 2460 grams (max
             blood for study 6mL =3%)

          -  Postnatal age &lt; 14 days.

          -  Received loading dose of phenobarbital 20mg/kg and/or phenytoin.

          -  Ongoing clinical or electroencephalographic seizures despite this therapy.

          -  For whom parental consent to participate in the study is obtained.</inclusivecriteria>
    <inclusiveminage>37</inclusiveminage>
    <inclusiveminagetype>Weeks</inclusiveminagetype>
    <inclusivemaxage>42</inclusivemaxage>
    <inclusivemaxagetype>Weeks</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Serum creatinine greater than 1.2 at enrollment or greater than 2.0 at any time.

          -  Biochemical abnormality - hypoglycemia, hypocalcemia- that when treated result in
             seizure cessation.

          -  Severe hypoxic ischemic injury likely to result in imminent death</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>18</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Richard H. Haas</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Pediatric Pharmacology Research Units Network</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Thrasher Research Fund</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the correct dosing for intravenous levetiracetam in
      term new born babies with seizures. In addition information on safety and efficacy will be
      collected. This new anticonvulsant drug is a promising treatment for seizures in newborns.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00461409</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Richard Haas, MBBChir</name>
      <address>University of California, San Diego</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>